Global Engage

BIOLOGICS & BIOSIMILARS CONGRESS : ASIA

VACCINES R&D & COMMERCIALISATION CONGRESS: ASIA

AN INTERACTIVE FORUM ON RESEARCH, DEVELOPMENT AND COMMERCIALISATION OF BIOLOGICS, BIOSIMILARS AND VACCINES

– SINGAPORE –

27-28 November 2018



www.global-engage.com

WARM WELCOME

Global Engage

Global Engage is pleased to announce that the **Biologics and Biosimilars Congress, co-located with Vaccines R&D and Commercialisation Congress Asia** will take place on the 27th and 28th November, 2018 in Singapore, as part of the Drug Discovery Series. The congress will bring together an even split of industries and researchers to discuss on the latest biologics science, the development of partnership and commercial collaborations in this scientific sphere.

Biologics make up an estimated 25 to 30 percent of therapeutic agents on the market today and is expected to hit $200 billion over the next few years. This demand for therapeutic biologics has exceeded what can be provided by traditional discovery and development process. Over 338 monoclonal entities are currently in clinical trials, 170 monoclonal antibodies are in development for cancer and over a third of clinical trials for cancer vaccines are in progress in Asia Pacific.

In the last decade, Asian biopharmaceutical companies are developing more products for commercialisation in the global market and international drug companies have moved many R&D functions and commercial operations to the APAC region. Expanding infrastructures, an evolving regulatory system and a large number of potential trial subjects make Asia an important global hub for biological drug development.

Attracting industry, regulatory and academic experts working in all areas of antibody, protein, biosimilars and vaccines, this two-day meeting will provide you with the opportunity to take home cutting edge strategies, case studies, regulatory guidelines and commercialisation partnerships. Keep abreast of your competitors and stay on top of the latest technology and solution advancements in this area. This will be achieved through a vibrant exhibition room full of technology providers showcasing their solutions and platforms, networking breaks allowing interactive discussions and formation of collaborations, poster presentations and expert led case study presentations with incisive panel discussions across both days.

EXPERT SPEAKERS Include:

JIAN NI
President of R&D, Nuance Biotech Inc, China, CEO, The National Engineering Research Center of Antibody Medicine, China

BRIAN GREVEN
Director of Clinical Manufacturing, Samsung Biologics, South Korea

ABHISHEK KULSHRESTHA
Chief Scientific Manager, Biocon Research, India

SITTIPONG LIAMSUWAN
Policy and Access Director, MSD, Thailand

PRITU DHALARIA
Director – Immunization Technical Support Unit, Ministry of Health, India

SUNG NYEO SHIM
Executive Director, Chong Kun Dang (CKD Pharm), South Korea

HUNG-KAI KEVIN CHEN
Chief Executive Officer, Elixiron Immunotherapeutics Inc.

PRITU DHALARIA
Director – Immunization Technical Support Unit, Ministry of Health, India

JIAN NI
President of R&D, Nuance Biotech Inc, China, CEO, The National Engineering Research Center of Antibody Medicine, China

SITTIPONG LIAMSUWAN
Policy and Access Director, MSD, Thailand

ZHIWEI SONG
Principal Scientist, Bioprocessing Technology Institute, A*Star, Singapore

ASHOK KUMAR PATRA
Director, Biologics Development, Imgenex, India

TARUN SALUJA
Research Scientist, International Vaccine Institute, Korea

SU TRAN TO CHINH
Senior Research Fellow, Bioinformatic Institute, A*Star, Singapore

RAMLI ZAINAL
Director, National Pharmaceutical Regulatory Agency, Malaysia

BRIAN GREVEN
Director of Clinical Manufacturing, Samsung Biologics, South Korea

AYAN DEY
Research Scientist, International Vaccine Institute, Korea

ABHISHEK KULSHRESTHA
Chief Scientific Manager, Biocon Research, India

PARESH VADGAMA
Team Leader – Formulation Development, Glenmark Pharmaceuticals, Switzerland

ALIREZA GHOLAMI
Director – Human Rabies Vaccine Unit, Pasteur Institute of Iran, Iran

PETER WANG
Vice President, CMAB, China

SYED TAHMEED
Country Head & Director Sanofi Pasteur, Bangladesh

JINGXIAN LIU
Structural Biology Group Leader, Principal Scientist, Shanghai Chempartner, China

ABHIMANYU SAXENA
National Program Officer, Vaccines Logistics and Cold Chain Management, United Nation Development Program, India

GUIDO DIETRICH
VP Quality Biologics & Steriles, Merck, Sharpe & Dohme, Germany

SITTICHAI N.
Director of Civil Servant Medical Benefit Scheme (CSMBS), Ministry of Finance, Thailand

ANGELA GOODENOUGH
Senior Director, Wuxi Biologics, China

POH CHIT LAA
Distinguished Professor & Head, Centre for Virus and Vaccine Research, Sunway University, Malaysia

ISABEL YEE PINN TSIN
Research Fellow, Sunway University, Malaysia

SYLVIE ALONSO
Associate Professor - Department of Microbiology and Immunology, University of Singapore

MIREILLE LAHOUD
Associate Professor, Monash Biomedicine Discovery Institute, Monash University

08:00-08:50 Registration & Refreshments

BIOLOGICS AND BIOSIMILARS CONGRESS ASIA

Global Engage Welcome Address and Morning Chair's Opening Remarks

09:00-09:30

SUNG NYEO SHIM
Executive Director, Chong Kun Dang (CKD Pharm), South Korea

Title TBC

09:30-10:00

HUNG-KAI KEVIN CHEN
Chief Executive Officer, Elixiron Immunotherapeutics Inc.

New Strategies for next generation cancer immunotherapy: Targeting tumor-associated macrophages

The immune landscape of tumor microenvironment (TME) contribute significantly to tumor progression and metastasis. Since tumor-associated macrophages (TAMs) are the most abundant host immune cells in the TME, we set forth to investigate the functional polarization of TAMs using clinical samples from cancer patients. Interestingly, TAMs from metastatic tumors displayed a predominant M2 phenotype, whereas those from primary tumors had a mixed expression of both M1 and M2 markers. In addition, we found that M2-polarized TAMs secreted interleukin-35 (IL-35), an immunosuppressive cytokine, to modulate epithelial plasticity of cancer cell and promote metastatic colonization. Neutralization of IL-35 or ablation of macrophages reduces cancer metastasis. In preclinical animal models, therapeutic effects of anti-IL-35 can be further improved by combination therapy with anti-CSF-1R, a potential TAM-targeting immunotherapy in clinical development for solid cancers. Our results indicate the distinct TMEs of primary and metastatic tumors and provide potential targets for intercepting metastasis and holding tumor progression. Elixiron's scientists are currently developing therapeutic antibodies against both IL-35 and CSF-1R, enabling the future development of IL-35/CSF-1R bi-specific antibodies as next generation cancer immunotherapy.

10:00-10:30

SOLUTION PROVIDER PRESENTATION

For sponsorship opportunities please contact Reuben Raj
reuben@global-engage.com / +60321175221

VACCINES R&D AND COMMERCIALISATION CONGRESS ASIA

Global Engage Welcome Address and Morning Chair's Opening Remarks

09:00-09:30

ALIREZA GHOLAMI
Director – Human Rabies Vaccine Unit, Pasteur Institute of Iran, Iran

Establishing a rabies minigenome in order to obtain reverse genetic system for rabies rescue viruses

09:30-10:00

PRITU DHALARIA
Director – Immunization Technical Support Unit, Ministry of Health, India

Immunization Program Launched by Government of India to reach the un-reach children for Immunization - Mission Indradhanush

This initiative has drawned eyes all over the world. The Mission Indradhanush aims to cover all those children by 2020 who are either unvaccinated, or are partially vaccinated against vaccine preventable diseases. India's Universal Immunisation Programme (UIP) provide free vaccines against 12 life threatening diseases, to 26 million children annually. The Universal Immunization Programme provides life-saving vaccines to all children across the country free of cost to protect them against Tuberculosis, Diphtheria, Pertussis, Tetanus, Polio, Hepatitis B, Pneumonia and Meningitis due to Haemophilus Influenzae type b (Hib), Measles, Rubella, Japanese Encephalitis (JE) and Rotavirus diarrhoea. (Rubella, JE and Rotavirus vaccine in select states and districts).

10:00-10:30

SOLUTION PROVIDER PRESENTATION

For sponsorship opportunities please contact Reuben Raj
reuben@global-engage.com / +60321175221

10:30-11:30 Morning Refreshments / Poster Presentations / One-to-One Meetings

11:30-12:05

PANEL DISCUSSION:

Emerging Biotherapies and Its Challenges

JIAN NI
President of R&D, Nuance Biotech Inc, China, CEO, The National Engineering Research Center of Antibody Medicine, China

12:05-12:30

ZHIWEI SONG
Principal Scientist, Bioprocessing Technology Institute, A*Star, Singapore

Glycoengineering of CHO cells for producing fucose-free rituximab and GA101 and human β-glucocerebrosidase (Cerezyme) with mannose-terminated N-glycans

Glycosylation can significantly affect the efficacy of recombinant therapeutics. Glycoprotein drugs, such as EPO, require a high degree of sialylation on their N-glycans in order to have a longer

11:30-12:05

PANEL DISCUSSION:

Improving Patients Access to Immunization: Access and Distribution of Vaccines in Asia

SITTIPONG LIAMSUWAN
Policy and Access Director, MSD, Thailand

PRITU DHALARIA
Director – Immunization Technical Support Unit, Ministry of Health, India

12:05-12:30

SITTIPONG LIAMSUWAN
Policy and Access Director, MSD, Thailand

Access of Vaccines in Thailand

Medicine or Vaccine has its most value when it has optimal access. National reimbursement maximizes the coverage, not necessary optimizes the access. Reimbursement increases the pool but whether patients in the pool are funneled to the actual "action" of receiving medicine depends various factors. According to AIDA buyer's journey, before funneling

12:05-12:30

circulatory half-life. Mannose-terminated N-glycans can target the protein to dendritic cells and macrophages cells via their cell surface mannose-binding receptors. Removal of core fucose from human IgG1 antibodies has been shown to significantly enhance its affinity to Fc□RIIIa and thereby dramatically improves its antibody-dependent cellular cytotoxicity (ADCC) activity. With cytotoxic lectins and genome editing tools we have isolated/ created more than 30 CHO glycosylation mutant cell lines. Many of these mutants are able to produce IgG antibodies with one major N-glycan which represents 90-97% of the total N-glycans attached to the antibody. In this presentation, I will describe the development of stable cell lines to produce fucose-free rituximab and GA101. In a cell-based ADCC assay, these fucose-free antibodies outperformed their commercial counterparts, Rituxan and Gazyva, respectively. We have also developed stable cell lines to produce recombinant human β-glucocerebrosidase with mannose-terminated N-glycans (mainly Man5). These data demonstrated potential applications of glycoengineered CHO cells in production of recombinant therapeutics.

12:05-12:30

to the action, "awareness", "interest", and "desire" to receive medicine is crucial. These three factors require collaborations between key stakeholders including both public and private partner. This session will demonstrate an example of Public-private partnership that has led to optimal access of vaccines in Thailand.

12:30-13:00

SOLUTION PROVIDER PRESENTATION

For sponsorship opportunities please contact Reuben Raj
reuben@global-engage.com / +60321175221

12:30-13:00

SOLUTION PROVIDER PRESENTATION

For sponsorship opportunities please contact Reuben Raj
reuben@global-engage.com / +60321175221

13:00-14:00 Lunch / Poster Presentations / One-to-One Meetings

BIOLOGICS AND BIOSIMILARS CONGRESS ASIA

14:00-14:25

ASHOK KUMAR PATRA

Director, Biologics Development, Imgenex, India

Biosimilars: A Process driven Product Development Technology

Despite decades of advancement in characterization analytics, biosimilar development still are largely defined by the manufacturing processes used to make them as the focus of the development is to tackle the COGs and time to market. Until recently, perfusion culture was used in biomanufacturing almost exclusively for difficult-to-express (low-titer) proteins and those known to be sensitive to culture conditions. Batch/fed-batch processes could produce them, but by the time a culture was over, most of the early expressed proteins would have deteriorated beyond retrieval. Perfusion culture allows for high-density cultures that maximize productivity in relatively small bioreactors. It requires continual feeding – and thus uses up large volumes of culture media/supplements – as well as continuous removal of metabolites and product, with dilution rates exceeding the cell growth rate. This requires a means of retaining cells in a bioreactor while removing (and replacing) the supernatant around them. However, Impressive technological advances in process engineering enabled continuous bioprocessing a reality. This has inherent advantage of higher productivity which can facilitate implementation of small process trains, resulting in cost-effective, lean, and agile manufacturing facilities. Hollow-fiber fitted with bioreactors offer alternate solution to batch perfusion strategy for cell culture. With new technological advancements utilization of alternate tangential flow filtration system which while controlling the rate of perfusion helps removal of metabolites and enhances the cell growth and production.

14:25-14:50

SU TRAN TO CHINH

Senior Research Fellow, Bioinformatic Institute, A*Star, Singapore

Antibody Engineering of Therapeutic Antibody Elements: A detailed investigation into the various regions and their impact

Monoclonal antibody based therapy has made its mark in targeted therapy in the last few decades, especially in the example of Herceptin® against Her2-positive cancers. To investigate the various antibody regions and their effects on binding, our APD Lab modified the various elements in

VACCINES R&D AND COMMERCIALISATION CONGRESS ASIA

14:00-14:25

TARUN SALUJA

Research Scientist, International Vaccine Institute, Korea

Typhoid Vaccine Clinical Development

14:25-14:50

RAMLI ZAINAL

Director, National Pharmaceutical Regulatory Agency, Malaysia

Developments in Biological Drug Controls

14:25-14:50

Herceptin®/Trastuzumab and Perjeta®/Pertuzumab to investigate their effects on recombinant expression, purification, antigen binding, and more recently, receptor binding. Summarizing the work of a number of years on the activity of the light chain, VH-VL pairings, and even the constant regions, there is a need to perhaps re-think how antibodies are looked at, especially when engineered for therapeutic purposes.

14:25-14:50

Continued

14:50-15:20

SOLUTION PROVIDER PRESENTATION

For sponsorship opportunities please contact Reuben Raj
reuben@global-engage.com / +60321175221

14:50-15:20

SOLUTION PROVIDER PRESENTATION

For sponsorship opportunities please contact Reuben Raj
reuben@global-engage.com / +60321175221

15:20-15:45

BRIAN GREVEN

Director of Clinical Manufacturing, Samsung Biologics, South Korea

Problems with predicting the product quality of a high titer monoclonal antibody cell line

Scaling up the cell culture and harvest processes from 2L and 10L to 1000L may be difficult to model and predict performance due to the large scale specific parameters. This is a case study of a high titer producing monoclonal antibody cell line that had different product quality attributes when it was scaled up from 2L and 10L to 1000L. 2L and 10L bioreactors are used as the production bioreactor to determine cell production performance and also to produce material for further purification analysis. The 2L and 10L bioreactors are designed to mimic the production environment in the larger production bioreactors, which in this case study it was a 1000L bioreactor. Unfortunately not all parameters can be simulated at the 2L and 10L scale including the Harvest conditions. The inability to model all of the parameters that will be performed at the larger scale can lead to some product quality surprises at the larger scale. In our case the larger scale production bioreactor and harvest produced different product quality attributes than observed at the smaller scale. To investigate the differences in the product quality attributes a small scale model was created to simulate the conditions in the production bioreactor prior to and during the harvest step. This case study will present how the model was determined and implemented for the 1000L process.

15:20-15:45

AYAN DEY

Research Scientist, International Vaccine Institute, Korea

Building Affordable and Sustainable Vaccines for Neglected Diseases in Developing Countries

International Vaccine Institute (IVI) in Seoul, Korea, is an independent international organization which was initiated by United Nations Development Program (UNDP), devoted to development and introduction of new and improved vaccines. Our approach is based on different components: vaccine R&D, translational research, partnerships – product development partnerships, international research consortia, capacity-building – training and technology transfers. We developed low-cost killed whole-cell oral cholera vaccine with partners in Vietnam, Sweden, Korea and India, resulting in Shanchol and Euvichol-Plus. Shanchol was WHO-prequalified in September 2011 and Euvichol-Plus was WHO prequalified in August 2017. IVI has completed development of a typhoid conjugate which consists of the Vi polysaccharide from Salmonella Typhi conjugated to diphtheria toxoid (DT). This new typhoid conjugate vaccine (Vi-DT) promises to protect infants as well as young children against typhoid fever. IVI has transferred the technology of Vi-DT to two manufacturing partners and is working with them to complete the clinical development aimed at licensure and WHO prequalification. The products from two partner manufacturers have completed phase I clinical trials. IVI is also working on development of shigella, non-typhoid salmonella and hepatitis A vaccines for developing world.

15:45-16:45 Afternoon Refreshments / Poster Presentations / One-to-One Meetings

BIOLOGICS AND BIOSIMILARS CONGRESS ASIA

15:20-15:45

ABHISHEK KULSHRESTHA

Chief Scientific Manager, Biocon Research, India

Establishing Biosimilarity

Biosimilars bring the prospect of affordable healthcare and wide reach to large number of patient population. Also, these provide clinicians various cost effective options to manage difficult to treat medical conditions leading to enhanced progression free survival or improved quality of life for patients. This puts the onus on the manufacturers to design, develop and manufacture a quality product that is highly similar to the reference product. Considering the complex nature of these molecules regulatory agencies have been very circumspect about the pathways and approaches to establish biosimilarity of a proposed biosimilar to a reference product. In this regard agencies have evolved guidances that recommend a stepwise strategy to address biosimilarity using a totality of evidence approach. This presentation with the help of case studies from few approved biosimilars attempts to build a case for a practical and scientifically sound approach, that takes into consideration different variables and challenges arising out of among other things variability of reference product lots, performance of analytical methods, limitations of statistical methods etc., that may play a role in a realistic setting while developing a highly similar biosimilar product within the ambit of totality of evidence.

VACCINES R&D AND COMMERCIALISATION CONGRESS ASIA

15:20-15:45

WILLIAM FINCH (Reserved)

CEO, Oxford Vacmedix, UK

Title TBC

17:10-17:35

PARESH VADGAMA
Team Leader – Formulation Development,
Glenmark Pharmaceuticals, Switzerland
Title TBC

17:10-17:35

LUKASZ KURYK (Reserved)
Director – Clinical Science, Targovax Oy, Finland
Title TBC

17:45 Chair's Closing Remarks / End of Day One

MEDIA PARTNERS

08:00-09:00 Refreshments

BIOLOGICS AND BIOSIMILARS CONGRESS ASIA

Morning Chair

09:00-09:30

JIAN NI

President of R&D, Nuance Biotech Inc, China
CEO, The National Engineering Research Center of Antibody Medicine, China

New Immunomodulatory Targets and Next Generation Active Immune Checkpoint Control Immunotherapy

Despite the success of immunomodulatory antibodies in immuno-oncology, challenges remain in expanding the target space, developing next-generation immune checkpoint inhibitors and active immune checkpoint control immunotherapy with improved efficacy and safety, and addressing innate and acquired resistance to immunotherapy. This presentation focuses the leading immunomodulatory pathways as well as therapeutic targets we have identified in B7 superfamily members : B7-H1(PD-L1, B7-H2 (ICOSL), B7-H3 and B7-H4, TNF ligands and receptor superfamily: Blys (THANK), DR3 (TNFR25), DR4, DR5, DR6, GITR (AITR, TNFR18), GITRL, TR2, LIGHT, TR6, TL1A, RANK, TNFRSF19, RELT, TR1 (DcR3), DcR1and DcR2, Siglecs family: Siglec 5, 7, 8, 9, 10, 11 and Galectin family: Galectin 9, 10, 11, 12.

09:30-10:00

PETER WANG

Vice President, CMAB, China

Glycoengineering of CHO cells for producing fucose-free rituximab and GA101 and human β-glucocerebrosidase (Cerezyme) with mannose-terminated N-glycans

10:00-10:30

SOLUTION PROVIDER PRESENTATION

VACCINES R&D AND COMMERCIALISATION CONGRESS ASIA

Morning Chair

09:00-10:00

JOINT PRESENTATION: MIREILLE LAHOUD

Associate Professor, Monash Biomedicine Discovery Institute, Monash University

Dendritic Cell Receptors: Pattern Recognition and Immune Modulation

Dendritic cells (DC) use a variety of cell surface receptors to monitor the environment for potential dangers, including cells that have died of non-homeostatic causes (eg. infected cells), to induce appropriate immune responses. One such example is the DC-specific Damage-Associated Molecular Pattern receptor, Clec9A, that is expressed by mouse and human cross-presenting DC. Clec9A recognises dead cells and facilitates cross-presentation of dead cell-derived Ag and the induction of immune responses. Our research is focussed on elucidating the molecular interactions that underpin Clec9A function, the role of these interactions in mediating immune responses, and on developing Clec9A-mediated approaches for vaccine development and immune modulation.

SYLVIE ALONSO

Associate Professor - Department of Microbiology and Immunology, University of Singapore

Boosting the immunogenicity of the universal flu antigen vaccine candidate M2e via Clec9A targeting strategy

The highly conserved ectodomain of M2 protein (M2e) has been identified as a promising universal flu vaccine antigen candidate that would overcome the limitations encountered with current seasonal flu vaccines. However, its low immunogenicity has slowed down its clinical development and novel vaccine approaches are needed to improve the protective potential of M2e. Here we propose to target M2e to a specific sub-population of dendritic cells (mouse CD8+/human CD141+ DCs) as a way to boost the immunogenicity of M2e. This is achieved by engineering a chimeric anti-Clec9A monoclonal antibody fused at each of both heavy chains with three copies of the 24-amino acid M2e antigen. Our results so far demonstrate the induction in mice of significantly higher anti-M2e antibody titers upon single administration of the Clec9A-M2e construct compared to non-targeting GL117-M2e construct. This single dose regimen afforded up to 87.5% protection from lethal H1N1 flu challenge, accompanied with a significant reduction in the lung viral loads, and minimal lung pathology. These data thus support that Clec9A targeting of M2e represents a promising approach to overcome the inherent low immunogenicity of M2e. As the equivalent DC sub-population exists in humans, translation to human should be possible.

10:00-10:30

SOLUTION PROVIDER PRESENTATION

10:30-11:30 Morning Refreshments / Poster Presentations / One-to-One Meetings

11:30-12:05

PANEL DISCUSSION:

Sustaining the value proposition of biosimilars in the future

JINGXIAN LIU

Structural Biology Group Leader, Principal Scientist
Shanghai Chempartner, China

11:30-12:05

PANEL DISCUSSION:

Vaccines in the Next Decade (Scientific advances and Innovative Tech to design and deliver, novel tools and approaches to increase uptake on vaccines in Asia)

JIAN NI

President of R&D, Nuance Biotech Inc, China,
CEO, The National Engineering Research Center of Antibody Medicine, China

SYED TAHMEED

Country Head & Director, Sanofi Pasteur, Bangladesh

AYAN DEY

Research Scientist, International Vaccine Institute, Korea

12:05-12:30

LEI SHI (Reserved)

Executive Director, Zai Lab, China

Title TBC

12:05-12:30

SYED TAHMEED

Country Head & Director, Sanofi Pasteur, Bangladesh

Title TBC

12:30-13:00

SOLUTION PROVIDER PRESENTATION

For sponsorship opportunities please contact Reuben Raj
reuben@global-engage.com / +60321175221

12:30-13:00

SOLUTION PROVIDER PRESENTATION

For sponsorship opportunities please contact Reuben Raj
reuben@global-engage.com / +60321175221

13:00-14:00 Lunch / Poster Presentations / One-to-One Meetings

14:00-14:25

DENISE DOOLAN (Reserved)

Deputy Director, AITHM, Australia

Title TBC

14:00-14:25

ABHIMANYU SAXENA

National Program Officer, Vaccines Logistics and Cold Chain Management, United Nation Development Program, India

Improving Efficiency of Vaccination Systems in Multiple States, Abhimanyu Saxena

14:25-14:50

GUIDO DIETRICH

VP Quality Biologics & Steriles, Merck, Sharpe & Dohme, Germany

Operational Excellence in the Development of Biologics and Vaccines

Biologics and Vaccines are continuously growing in importance in the pharmaceutical world. In recent years, they have revolutionized the therapy of multiple diseases, like cancer and chronological-inflammatory disorders. The growing importance of these biological drugs requires higher sophistication in their manufacturing, testing, release and distribution. Over the last years there have been multiple technological and operational advances in these areas, like the continuously growing utilization of single use technology and increased digitization. Dr. Guido Dietrich will provide examples of the utilization of Operational Excellence and Quality by Design Tools and Methodologies in manufacturing of Biologics and Vaccines.

14:00-14:25

SITTICHAI N.

Director of Civil Servant Medical Benefit Scheme (CSMBS), Ministry of Finance, Thailand

Healthcare Financing for CSMBS Patients

14:50-15:15

ANGELA GOODENOUGH

Senior Director, Wuxi Biologics, China

Strategies for Managing Global Filings

14:50-15:15

ISABEL YEE PINN TSIN

Research Fellow, Sunway University, Malaysia

Design of live attenuated vaccines for Enterovirus 71

Besides mild HFMD, Enterovirus A71 (EV-A71) can cause severe neurological complications and fatality. From 2008-2014 there were 43.73% of HFMD cases due to EV-A71 in China. Up to date, there is no WHO-approved vaccine. This study demonstrated 2 live attenuated vaccines (LAV) which decreased viral replication in vitro, whilst conferring protection in 2-week old ICR mice against paralysis. The first LAV was a multiply mutated strain [EV71 (MMS)] which carried 6 additional nucleotide substitutions in the genome that had a partial deletion (Δ11bp, 5'-NTR). Another LAV (pIY), was engineered to carry microRNA

14:50-15:15

Continued

15:15-15:40

MICHAEL KIM (Reserved)
CEO, Prestige Biopharma, Singapore
Title TBC

14:50-15:15

target genes let-7a and miR-124a allowing endogenous RNA silencing in specific cell types. The cytopathic effects, viral RNA copy number, and plaque counts of the pIY vaccine strain was significantly lower in cells that expressed let-7a and miR-124a. Both the EV71 (MMS) and pIY vaccine strains were able to protect 2-week old mice from hind limb paralysis, showed high amounts of protective IFN-γ and conferred cross-protective immunity against sub-genotypes B3, B4, C1 and C4. There was absence of EV-A71 antigen in the skeletal muscles of mice vaccinated with the EV71 (MMS) and pIY strains. These vaccine strains are promising LAV candidates to be developed against fatal EV-A71 infections.

15:15-15:40

THOMAS EVANS (Reserved)
CEO & Board Director, Vaccitech, UK
Title TBC

15:40 Closing Remarks / Conference Close

POSTER PRESENTATIONS

MAKING A POSTER PRESENTATION

Poster presentation sessions will take place in breaks and alongside the other breakout sessions of the conference. Your presentation will be displayed in a dedicated area, with the other accepted posters from industry and academic presenters. We also issue a poster eBook to all attendees with your full abstract in and can share your poster as a PDF after the meeting if you desire (optional). Whether looking for funding, employment opportunities or simply wanting to share your work with a like-minded and focused group, these are an excellent way to join the heart of this congress.

In order to present a poster at the congress you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). We charge an admin fee of $50 to industry delegates to present, that goes towards the shared cost of providing the poster presentation area and display boards, guides etc. This fee is waived for those representing academic institutions and not for profit organisations.

DON'T DELAY, BOOK YOUR PLACE TODAY!

Places are limited and are based on a first come, first served basis so to avoid disappointment contact us today to reserve your place at Global Engage's Biologics & Biosimilars Congress / Vaccines R&D & Commercialisation Congress: Asia on 27-28 November 2018.

PHONE BOOKING

+603 2117 5193

Our conference team will make all the necessary arrangements.

ONLINE BOOKING

Visit the website to book your place with credit card payment or an invoice request.

www.global-engage.com/event/vaccines-commercialisation-congress-asia

THE CONGRESS PACKAGE INCLUDES:

All Conference Sessions
Lunches and Refreshments
Access to Exhibition Room
Conference Workbook
E-Document Pack

HOTEL ACCOMMODATION

Hotel accommodation will be available at a group rate.

FREE NEWSLETTER

For updates on the Biologics & Biosimilars Congress / Vaccines R&D & Commercialisation Congress: Asia, plus free resources and reports, as and when our speakers authorise their release dates, check for updates at:

www.global-engage.com/event/vaccines-commercialisation-congress-asia

SPONSORSHIP AND EXHIBITION OPPORTUNITIES AVAILABLE

For more details contact: reuben@global-engage.com Tel: **+60321175221**

Rita: rita@global-engage.com / +60 321 175 193
Irina: irina@global-engage.com / +61 (0) 429 477 350
www.global-engage.com

Asia Pacific Office: Global Engage Sdn Bhd, Level 33, Ilham Tower, No. 8 Jalan Binjai, 50450 Kuala Lumpur, Malaysia

Follow Us
@Lifesciences_GE